(R)-3-isobutylaminopiperidine-1-carboxylic acid tert-butyl ester | 1027346-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (R)-3-isobutylaminopiperidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl (3R)-3-[(2-methylpropyl)amino]piperidine-1-carboxylate；(R)-tert-Butyl 3-[(2-methylpropyl)amino]piperidine-1-carboxylate；tert-butyl (3R)-3-(2-methylpropylamino)piperidine-1-carboxylate
• CAS: 1027346-39-9
• 化学式: C₁₄H₂₈N₂O₂
• 分子量: 256.389
• InChiKey: IYSSNDNZJKNZSX-GFCCVEGCSA-N

物化性质

• 沸点：
  333.9±35.0 °C(Predicted)
• 密度：
  0.98±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-3-isobutylaminopiperidine-1-carboxylic acid tert-butyl ester 、 4-chloro-8-(cyclohexylmethoxy)quinoline-2-carbonyl chloride 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 (R)-3-[(4-chloro-8-(cyclohexylmethoxy)quinoline-2-carbonyl)isobutylamino]piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] QUINOLINE DERIVATIVES AS RENIN INHIBITORS
  [FR] DÉRIVÉS DE QUINOLÉINE UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉNINE

  摘要：

  公开号：

  WO2013088452A3
• 作为产物：
  描述：

  在 CH₃CH₂CH₂CH₂NH₂ 作用下， 以 二氯甲烷 为溶剂， 以90%的产率得到(R)-3-isobutylaminopiperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Discovery of a series of aminopiperidines as novel iNOS inhibitors

  摘要：

  Nitric oxide (NO), a mediator of various physiological and pathophysiological processes, is synthesized by three isozymes of nitric oxide synthase (NOS). Potential candidate clinical drugs should be devoid of inhibitory activity against endothelial NOS (eNOS), since eNOS plays an important role in maintaining normal blood pressure and flow. A new series of aminopiperidines as potent inhibitors of iNOS were identified from a HTS lead. From this study, we identified compound 33 as a potent iNOS inhibitor, with >25-fold selectivity over eNOS and 16-fold selectivity over nNOS. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2007.10.073

文献信息

• Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors
  作者：Yasuhiro Imaeda、Michiko Tawada、Shinkichi Suzuki、Masaki Tomimoto、Mitsuyo Kondo、Naoki Tarui、Tsukasa Sanada、Ray Kanagawa、Gyorgy Snell、Craig A. Behnke、Keiji Kubo、Takanobu Kuroita

  DOI：10.1016/j.bmc.2016.09.030

  日期：2016.11

  The action of the aspartyl protease renin is the rate-limiting initial step of the renin-angiotensin-aldosterone system. Therefore, renin is a particularly promising target for blood pressure as well as onset and progression of cardiovascular and renal diseases. New pyrimidine derivatives 5–14 were designed in an attempt to enhance the renin inhibitory activity of compound 3 identified by our previous

  天冬氨酰蛋白酶肾素的作用是肾素-血管紧张素-醛固酮系统的限速起始步骤。因此，肾素是血压以及心血管和肾脏疾病的发作和发展的特别有希望的靶标。设计新的嘧啶衍生物5 – 14是为了增强化合物3的肾素抑制活性，这种化合物是通过我们以前的基于片段的药物设计方法确定的。引入对于在催化位点与两种天冬氨酸相互作用必不可少的碱性胺，并优化S1 / S3结合元素，包括通过Leu114诱导拟合的结构改变（Leu114由“ Leu-in”变为“ Leu-out”）。基于合理结构的药物设计方法导致了N的发现-（piperidin-3-yl）pyrimidine-5-carboxamide 14，比化合物3强65,000倍的有效肾素抑制剂。出人意料的是，化合物14的抑制活性的这种显着增强已经通过仅向化合物3整体添加七个重原子而实现。化合物14在大鼠中显示出优于其他天冬氨酰蛋白酶的优异选择性和中等的口服生物利用度。
• AMIDE DERIVATIVE
  申请人：Nakahira Hiroyuki

  公开号：US20100056497A1

  公开（公告）日：2010-03-04

  The present invention relates to a compound of the formula (I) being useful as a renin inhibitor, or a pharmaceutically acceptable salt thereof. wherein R 1a is a hydrogen atom, an optionally substituted C 1-6 alkyl, etc.; R 1b is an optionally substituted C 1-6 alkoxy, etc.; R 1c is a hydrogen atom, an optionally substituted C 1-6 alkoxy, etc.; R 2 is a hydrogen atom, an optionally substituted C 1-6 alkyl, etc.; R 3a , R 3b , R 3c and R 3d are independently the same or different, and each is a group of the formula: -A-B (in which A is a single bond, —(CH 2 ) s O—, —(CH 2 ) s N(R 4 )CO—, etc., B is a hydrogen atom, an optionally substituted C 1-6 alkyl, etc.), etc.; R 4 is a hydrogen atom, an optionally substituted C 1-6 alkyl, etc.; s is 0, etc.; and n is 1, etc.

  本发明涉及一种具有式(I)的化合物，其可用作肾素抑制剂，或其药学上可接受的盐。其中，R1a是氢原子，可选地取代的C1-6烷基等；R1b是可选地取代的C1-6烷氧基等；R1c是氢原子，可选地取代的C1-6烷氧基等；R2是氢原子，可选地取代的C1-6烷基等；R3a，R3b，R3c和R3d独立且相同或不同，每个是式：-A-B的基团（其中A是单键，-(CH2)sO-，-(CH2)sN(R4)CO-等，B是氢原子，可选地取代的C1-6烷基等）等；R4是氢原子，可选地取代的C1-6烷基等；s为0等；n为1等。
• AMIDE COMPOUNDS AND USE OF THE SAME
  申请人：Imaeda Yasuhiro

  公开号：US20100324010A1

  公开（公告）日：2010-12-23

  A renin inhibitor comprising a compound represented by the formula: wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof. The compound of the present invention has a superior renin inhibitory activity, and thus is useful as an agent for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension and the like.

  一种肾素抑制剂，包括一种由下式表示的化合物：其中每个符号如说明书中所定义，或其盐或前药。本发明的化合物具有优异的肾素抑制活性，因此可用作预防或治疗高血压、由高血压引起的各种器官损伤等的药剂。
• US8329691B2
  申请人：——

  公开号：US8329691B2

  公开（公告）日：2012-12-11
• [EN] QUINOLINE DERIVATIVES AS RENIN INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLÉINE UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉNINE
  申请人：SUN PHARMA ADVANCED RES CO LTD

  公开号：WO2013088452A3

  公开（公告）日：2013-10-03